DrugPatentWatch Database Preview
Patent: 8,748,626
» See Plans and Pricing
Summary for Patent: 8,748,626
| Title: | Oxazole and thiazole compounds as KSP inhibitors |
| Abstract: | Disclosed are new substituted oxazole and thiazole compounds of Formula (I) and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the derivatives together with pharmaceutically acceptable carriers, and uses thereof: ##STR00001## |
| Inventor(s): | Barsanti; Paul A. (Pleasant Hill, CA), Ding; Yu (Union City, CA), Han; Wooseok (San Ramon, CA) |
| Assignee: | Novartis AG (Basel, CH) |
| Application Number: | 13/640,561 |
| Patent Claims: | see list of patent claims |
Details for Patent 8,748,626
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | Start Trial | Novartis AG (Basel, CH) | 2039-02-26 | RX | search | |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 002 | 2017-06-22 | Start Trial | Novartis AG (Basel, CH) | 2039-02-26 | RX | Orphan | search |
| Genentech Inc | RITUXAN HYCELA | rituximab; hyaluronidase (human recombinant) | SOLUTION;SUBCUTANEOUS | 761064 | 001 | 2017-06-22 | Start Trial | Novartis AG (Basel, CH) | 2039-02-26 | RX | Orphan | search |
| Genentech | HERCEPTIN | trastuzumab | VIAL; INTRAVENOUS | 103792 | 001 | 1998-09-25 | Start Trial | Novartis AG (Basel, CH) | 2039-02-26 | RX | Orphan | search |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patent Family for US Patent 8,748,626
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011128388 | Start Trial |
| United States of America | 2013224186 | Start Trial |
| Japan | 2013525290 | Start Trial |
| European Patent Office | 2558452 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
